Zobrazeno 1 - 10
of 162
pro vyhledávání: ''
Autor:
Sudeep Banerjee, Robert J. Wechsler-Reya, Jill P. Mesirov, Alexander T. Wenzel, Hyunho Yoon, Huwate Yeerna, Chih-Min Tang, Mayra Yebra, Pablo Tamayo, Stephanie Ting, Jason K. Sicklick
Publikováno v:
Molecular Cancer Therapeutics. 20:2035-2048
Gastrointestinal stromal tumor (GIST) is commonly driven by oncogenic KIT mutations that are effectively targeted by imatinib (IM), a tyrosine kinase inhibitor (TKI). However, IM does not cure GIST, and adjuvant therapy only delays recurrence in high
Autor:
Douglas R. Spitz, Vishnu Menon, Kevin Cho, Michael C. Zahner, Yuting Wang, Naoshad Muhammad, Jin Zhang, Ramachandran Rashmi, Julie K. Schwarz, Xiaojing Huang, Buck E. Rogers, Gary J. Patti, Sisi Zhang, Yi Huang, Michael L. McCormick, Kay Jayachandran, Fiona Ruiz
Publikováno v:
Mol Cancer Ther
The purpose of this study was to determine if radiation (RT)-resistant cervical cancers are dependent upon glutamine metabolism driven by activation of the PI3K pathway and test whether PI3K pathway mutation predicts radiosensitization by inhibition
Autor:
Alexander J. Lazar, Roman Groisberg, Vivek Subbiah, Robert E. Brown, Daniella E Portal, Aung Naing, Neeta Somaiah, Maria Alejandra Zarzour, Cynthia E. Herzog, Jason Roszik, Anthony P. Conley, David S. Hong, Shreyaskumar Patel
Publikováno v:
Mol Cancer Ther
Overexpression of transcription factor 3 in alveolar soft part sarcoma(ASPS) results in upregulation of cell proliferation pathways. No standard treatment algorithm exists for ASPS; multikinase inhibitors[tyrosine kinase inhibitor (TKI)] and immune c
Autor:
Umang Shah, Matthew C. Coffey, Himanshu Kharkwal, Sanjay Goel, Allyson J. Ocean, Sengottuvel Viswanathan, Imran Chaudhary, M. H. Ghalib, Ruwan Parakrama, Radhashree Maitra
Publikováno v:
Molecular Cancer Therapeutics. 19:1148-1156
KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS-mutated cells, and is syn
Autor:
Weiwei Jin, Lianpeng Chang, Song Ye, Jiahong Jiang, Huaixiang Zhou, Yaping Xu, Liu Yang, Xiaoge Hu, Chao Ni
Publikováno v:
Molecular Cancer Therapeutics. 19:956-965
With the increase of treatment course, resistance to EGFR blockade is inevitable in patients with metastatic colorectal cancer (mCRC). KRAS mutations have been considered to be primary drivers of this resistance; however, the potential function of ot
Autor:
Sachin K. Khiste, Mohammad Burhan Uddin, Ronald A. Hill, Sami Nazzal, Zhijun Liu, Xin Gu, Salman B. Hosain, Kartik R. Roy, Yong-Yu Liu
Publikováno v:
Mol Cancer Ther
Ceramide (Cer) is an active cellular sphingolipid that can induce apoptosis or proliferation-arrest of cancer cells. Nanoparticle-based delivery offers an effective approach for overcoming bioavailability and biopharmaceutics issues attributable to t
Autor:
Takashi Kojima, Masahiro Yasunaga, Kenji Hirotani, Yasutoshi Kuboki, Toshihiko Doi, Takashi Kagari, Yoshikatsu Koga, Naoyuki Maeda, Yasuhiro Matsumura, Mayumi Yamauchi, Shigehiro Koganemaru
Publikováno v:
Molecular Cancer Therapeutics. 18:2043-2050
HER3 is overexpressed in several cancers, including colorectal cancer. Although therapies with anti-HER3 antibodies have been investigated, significant clinical benefits have not been reported. U3-1402 is a novel HER3-antibody–drug conjugate (ADC)
Autor:
Thomas Roeder, Lia Burkhardt, Judith Bossen, Line Steen, Iris Bruchhaus, Karin Uliczka, Christine Fink, Mandy Mong-Quyen Mai, Roxana Pfefferkorn, Michael Spohn, Holger Heine
Publikováno v:
Molecular Cancer Therapeutics. 18:1659-1668
Lung cancer is the leading cause of cancer-associated mortality. Mutations in the EGFR gene are among the most important inducers of lung tumor development, but success of personalized therapies is still limited because of toxicity or developing resi
Autor:
Luisa Izzi, H. Wang, Victor Cohen, Christian Couture, Nicole Bouchard, Jason Agulnik, Valerie Higenell, Normand Blais, Lise Tremblay, Cyrla Hoffert, Caroline Rousseau, Mathilde Couetoux du Tertre, Gerald Batist, Razvan Diaconescu, Maud Marques, Suzan McNamara, Vincent Pelsser, Karen Gambaro, Alan Spatz, Archana Srivastava
Publikováno v:
Molecular Cancer Therapeutics. 18:1628-1636
Rearrangements in the anaplastic lymphoma kinase (ALK) gene are found in approximately 5% of non–small cell lung carcinoma (NSCLC). Here, we present a comprehensive genomic landscape of 11 patients with ALK+ NSCLC and investigate its relationship w
Autor:
Alena Cristina Jaime-Ramirez, Yeshavanth Kumar Banasavadi-Siddegowda, Haroon Quadri, Tejaswini Nallanagulagari, Balveen Kaur, Mitra Nair, Tae Jin Lee, Manish K. Aghi, Ji Young Yoo, W. Shawn Carbonell, Joseph N. Liu, Kurt H. Bockhorst, Jeffrey Yunhua Guo, Jianying Zhang
Publikováno v:
Mol Cancer Ther
Integrin β1 receptor, expressed on the surface of tumor cells and macrophages in the tumor microenvironment (TME), has been implicated in both tumor progression and resistance to multiple modalities of therapy. OS2966 is the first clinical-ready hum